Ublituximab Plus Ibrutinib Versus Ibrutinib Alone For Patients With Relapsed Or Refractory High-Risk Chronic Lymphocytic Leukaemia (Genuine): A Phase 3, Multicentre, Open-Label, Randomised Trial (Vol 8, Pg E254, 2021)
LANCET HAEMATOLOGY（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要